An overview of thrombolytic treatment for pulmonary embolism: A single Centre experience

Basit Öğe Kaydı
dc.contributor.authorŞen H.S.
dc.contributor.authorAbakay Ö.
dc.contributor.authorSezgi C.
dc.contributor.authorYilmaz S.
dc.contributor.authorTaylan M.
dc.contributor.authorKaya H.
dc.contributor.authorTanrikulu A.C.
dc.date.accessioned2024-04-24T18:46:13Z
dc.date.available2024-04-24T18:46:13Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractIntroduction: A massive pulmonary embolism (MPE) has a poor prognosis and high mortality. Thrombolytic therapy is preferred in patients with life-threatening symptoms such as hypotension, cardiogenic shock, and right ventricular failure due to the risk of severe bleeding. Materials and methods: This is a retrospective analysis of patients who were hospitalized with the diagnosis of pulmonary embolism (PE) and given thrombolytic therapy in the chest diseases clinic of a tertiary university hospital between January 2008 and November 2013. Results: The subjects' mean age was 59.54 ± 13.76 years. Fourteen of 39 patients who were treated with thrombolytic therapy were male (35.89%) and 25 (64.10%) were female. The symptoms experienced by the patients included dyspnea in 39 patients, chest pain in 35 patients, hemoptysis in 6 patients, syncope in 13 patients and cough in 10 patients. Risk factors were advanced age (> 60 years) in 19, immobilization in 19, malignancy in 3, major surgery in 11 patients. The in-hospital mortality analysis showed that 32 patients were discharged and 7 patients died. Four patients died from their pulmonary embolism and 3 patients died because of a major bleeding complication. Conclusions: Pulmonary embolism is a disease that may lead to death within hours secondary to acute right heart failure. Early diagnosis and treatment can be life saving. Thrombolytic therapy has been shown to improve hemodynamic parameters in the early period post-PE. An increased risk of bleeding is one of the most important drawbacks of thrombolytic therapy. Nonetheless, it can be a life-saving therapy in properly selected patients.en_US
dc.identifier.endpage410en_US
dc.identifier.issn0393-6384
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84898448898
dc.identifier.scopusqualityN/A
dc.identifier.startpage403en_US
dc.identifier.urihttps://hdl.handle.net/11468/25112
dc.identifier.volume30en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBleeding Risken_US
dc.subjectPulmonary Embolismen_US
dc.subjectThrombolytic Treatmenten_US
dc.subjectTissue Plasminogen Activatoren_US
dc.titleAn overview of thrombolytic treatment for pulmonary embolism: A single Centre experienceen_US
dc.titleAn overview of thrombolytic treatment for pulmonary embolism: A single Centre experience
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu